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resections and reconstructions of the pulmonary artery no increased 
overall and pulmonary morbidity and mortality rate has been observed. 
The preservation of lung parenchyma has been indicated by some 
authors as the possible cause of a theoretical increased risk for loco-
regional recurrence after sleeve lobectomy. However, although in 
some experiences (Fadel’02) a higher local recurrence rate is reported 
for sleeve resection with advancing nodal status (N2), the few studies 
(Fadel’02,Terzi’02,Kim’05) analyzing risk factors for recurrence, show 
that the tumor stage and the nodal status are the only negative predic-
tive factors, rather than the type of operation performed. 
Table 2
Author (year) Complications (%)
Postoperative 
mortality (%)
Local recurrence 
(%)
Distant  
recurrence (%)
Sleeve Lobectomy
Gaissert (‘96) 11 4 14 -
Icard (‘99) 44 2.8 17 24
Okada (‘00) 13 8 -
Tronc (‘00) 16 1.6 22 11
Fadel (‘02) 16 2.9 15 11
Mezzetti (‘02) 10.8 3.6 20 -
Terzi (‘02) 14.5 12 5 18
Kim (‘05) 74.9 6.1 22 22
Ludwig (‘05) 38 4.3 - -
Pneumonectomy
Gaissert (‘96) 16 9 - -
Okada (‘99) 22 2 10 -
Deslauriers (‘04) - 5.3 35 -
Kim (‘05) 44 4.1 6 20
Ludwig (‘05) 26 4.6 - -
Postoperative quality of life has been advocated as one of the stron-
gest indicators that should inﬂuence the decision to perform a sleeve 
lobectomy rather than a pneumonectomy. A number of studies indicate 
that lung parenchyma sparing improves postoperative quality of life 
determining a greater cardio-pulmonary reserve, less pulmonary edema 
and less right ventricular dysfunction due to a lower pulmonary vascu-
lar resistance (Terzi’02,Martin-Ucar’02).
Special concern has been expressed by many thoracic surgeons when 
considering broncho-vascular reconstructive procedures after induction 
therapy, due to the signiﬁcantly higher risk of perioperative complica-
tions and mortality. Although only a few authors (Rendina’97,Ohta’03
,Stamatis’02) use sleeve resection routinely after neoadjuvant therapy, 
it has been proven in our experience (2,3), that also complex parenchy-
mal sparing operations can be performed after oncological treatment 
without increased morbidity and mortality rates observing long-term 
results comparable to those of the standard procedures (5-year survival: 
31%; local recurrence rate:15%). 
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Lobectomy with hilar and mediastinal lymph node dissection is the 
standard of care for patients with early stage non-small cell lung cancer 
(NSCLC). Wedge resection and segmentectomy, a parenchyma sparing 
anatomic resection, are limited resection options. The choice between 
lobectomy and limited resection is made by an assessment of the condi-
tion of the patient and associated risk of the operation, and the biology 
of the cancer. Perioperative mortality of lobectomy is 2-5%, but is 1% 
or less for limited resection. The main advantage of lobectomy is that it 
removes additional lung parenchyma and intralobar lymphatics which 
may contain micrometastatic tumor cells. The Lung Cancer Study 
Group (LCSG) randomized controlled trial of lobectomy versus open 
wedge resection for T1N0 NSCLC in 1995 found a marked increased 
risk of local recurrence, and a trend towards poorer survival that was 
not statistically signiﬁcant. Yet limited resection of lung cancer is a use-
ful option in select populations.
Limited resection is appropriate for patients who have insufﬁcient 
pulmonary reserve to tolerate lobectomy. Limited resection is also 
appropriate for patients with multifocal bronchioloalveolar carcinoma 
(BAC), who beneﬁt from complete resection of nodules, but whose 
entire normal lungs are at risk for disease recurrence. Additional patient 
populations may have equivalent outcomes with limited resection com-
pared with lobectomy. First, one observational study reported equiva-
lent survival among elderly patients with lobectomy or limited resec-
tion. Elderly patients, especially current and former smokers, are at risk 
for non-lung cancer related death, and the small oncologic beneﬁt of 
lobectomy may be outweighed by the upfront increased perioperative 
risk of lobectomy compared with limited resection in this population. 
Tumors smaller than 2cm and tumors associated with ground glass 
opacities (GGO) are being increasingly detected on computed tomogra-
phy. Observational studies suggest that limited resection for very small 
NSCLC, especially when associated with at least 50% GGO are associ-
ated with long term survival of greater than 90%, equivalent to survival 
of similar patients undergoing lobectomy. The LCSG trial had few 
patients with tumors smaller than 2cm. An ongoing randomized con-
trolled study in Japan and a planned trial in the US have been designed 
to further investigate optimal treatment of NSCLC smaller than 2cm. 
Finally, genomic analysis holds promise to guide therapy based on the 
biology of individual patient tumors. The future of lung cancer treat-
ment will involve treatment decisions, including extent or resection and 
beneﬁt of additional systemic therapies based on preoperative sampling 
of tumor genetic material. 
